Pelareorep

Oncolytics Biotech Inc. advances pelareorep therapy, showing significant survival benefits in breast cancer patients. Other biotech companies like Nurix, Incyte, Regeneron, and Foghorn also report promising developments in cancer treatments.

Recent cancer research breakthroughs include Oncolytics Biotech's BRACELET-1 study showing promising results for pelareorep in HR+/HER2- breast cancer, Novartis AG's FDA approval of Kisqali for early-stage breast cancer, Lantheus Holdings' positive Phase 3 SPLASH trial results for 177Lu-PNT2002 in prostate cancer, Sutro Biopharma's encouraging Phase 1b study data for Luvelta in ovarian cancer, and Zymeworks' upcoming presentation of preclinical data on its antibody-drug conjugate programs.

BRACELET-1 study results show improved overall survival (OS) and progression-free survival (PFS) when combining pelareorep with paclitaxel for HR-positive, HER2-negative advanced or metastatic breast cancer patients. The median OS was not reached with pelareorep/paclitaxel vs 18.2 months with paclitaxel alone, and the median PFS was 12.1 months vs 6.4 months. The overall response rate (ORR) was 37.5% with pelareorep/paclitaxel vs 13.3% with paclitaxel alone. These findings support further development of pelareorep in clinical settings.